Log in

BIOLASE Stock Price, News & Analysis (NASDAQ:BIOL)

$0.86
-0.03 (-3.39 %)
(As of 10/16/2019 08:25 AM ET)
Today's Range
$0.82
Now: $0.86
$0.94
50-Day Range
$0.75
MA: $0.96
$1.10
52-Week Range
$0.75
Now: $0.86
$2.87
Volume171,588 shs
Average Volume61,053 shs
Market Capitalization$18.77 million
P/E RatioN/A
Dividend YieldN/A
Beta2.25
BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Read More…

Industry, Sector and Symbol

Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BIOL
Previous SymbolNASDAQ:BLTI
CUSIPN/A
Phone949-361-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$46.15 million
Book Value$0.54 per share

Profitability

Net Income$-21,520,000.00

Miscellaneous

Employees190
Market Cap$18.77 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive BIOL News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.


BIOLASE (NASDAQ:BIOL) Frequently Asked Questions

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

When did BIOLASE's stock split? How did BIOLASE's stock split work?

BIOLASE shares reverse split before market open on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.

How were BIOLASE's earnings last quarter?

BIOLASE Inc (NASDAQ:BIOL) released its quarterly earnings data on Thursday, August, 8th. The medical technology company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.03. The medical technology company earned $8.65 million during the quarter, compared to analysts' expectations of $12.76 million. BIOLASE had a negative net margin of 47.46% and a negative return on equity of 159.26%. View BIOLASE's Earnings History.

When is BIOLASE's next earnings date?

BIOLASE is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for BIOLASE.

What price target have analysts set for BIOL?

4 equities research analysts have issued 1 year price objectives for BIOLASE's stock. Their predictions range from $2.00 to $3.00. On average, they expect BIOLASE's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 192.4% from the stock's current price. View Analyst Price Targets for BIOLASE.

What is the consensus analysts' recommendation for BIOLASE?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLASE.

Has BIOLASE been receiving favorable news coverage?

Media headlines about BIOL stock have been trending very negative recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. BIOLASE earned a news impact score of -3.3 on InfoTrie's scale. They also gave media stories about the medical technology company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the stock's share price in the immediate future. View News Stories for BIOLASE.

Are investors shorting BIOLASE?

BIOLASE saw a increase in short interest in September. As of September 15th, there was short interest totalling 585,000 shares, an increase of 11.4% from the August 15th total of 525,000 shares. Based on an average daily volume of 49,600 shares, the days-to-cover ratio is presently 11.8 days. Approximately 2.7% of the company's shares are sold short. View BIOLASE's Current Options Chain.

Who are some of BIOLASE's key competitors?

What other stocks do shareholders of BIOLASE own?

Who are BIOLASE's key executives?

BIOLASE's management team includes the folowing people:
  • Mr. Todd A. Norbe, Pres, CEO & Director (Age 52)
  • Mr. John R. Beaver, Exec. VP & CFO (Age 58)
  • Mr. Richard R. Whipp, VP of Operations (Age 67)
  • Mr. William E. Brown Jr., VP of Bus. Devel. (Age 71)
  • Mr. Daniel Merkin, National Sales Director (Age 46)

How do I buy shares of BIOLASE?

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $0.86.

How big of a company is BIOLASE?

BIOLASE has a market capitalization of $18.77 million and generates $46.15 million in revenue each year. The medical technology company earns $-21,520,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. BIOLASE employs 190 workers across the globe.View Additional Information About BIOLASE.

What is BIOLASE's official website?

The official website for BIOLASE is http://www.biolase.com/.

How can I contact BIOLASE?

BIOLASE's mailing address is 4 Cromwell, Irvine CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]


MarketBeat Community Rating for BIOLASE (NASDAQ BIOL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  230 (Vote Underperform)
Total Votes:  468
MarketBeat's community ratings are surveys of what our community members think about BIOLASE and other stocks. Vote "Outperform" if you believe BIOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Featured Article: Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel